MA32075B1 - Composes presentant une activite antagoniste de crth2 - Google Patents
Composes presentant une activite antagoniste de crth2Info
- Publication number
- MA32075B1 MA32075B1 MA33081A MA33081A MA32075B1 MA 32075 B1 MA32075 B1 MA 32075B1 MA 33081 A MA33081 A MA 33081A MA 33081 A MA33081 A MA 33081A MA 32075 B1 MA32075 B1 MA 32075B1
- Authority
- MA
- Morocco
- Prior art keywords
- heteroaryl
- aryl
- alkyl
- independently represent
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000003042 antagnostic effect Effects 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- -1 C3-C8 Chemical group 0.000 abstract 1
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 101100523290 Escherichia coli (strain K12) qorB gene Proteins 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
Abstract
L'invention porte sur des composés représentés par la formule générale (i), dans laquelle w représente chloro ou fluoro ; r1 représente phényle éventuellement substitué par un ou plusieurs substituants choisis parmi halo, -cn, alkyle en c1-c6, -sor3, -so2r3, -so2n(r2)2, -n(r2)2, -nr2c(o)r3, -co2r2, - conr2r3, -no2, -or2, -sr2, -o(ch2)por2, et -o(ch2)po(ch2)qor2, où les r2 représentent chacun indépendamment hydrogène, alkyle en c1-c6, cycloalkyle en c3-c8, aryle ou hétéroaryle ; les r3 représentent chacun indépendamment alkyle en c1-c6, cycloalkyle en c3-c8, aryle ou hétéroaryle ; p et q représentent chacun indépendamment un entier de 1 à 3 ; et sur leurs sels, hydrates, solvates, complexes ou promédicaments pharmaceutiquement acceptables, qui sont utiles dans des compositions administrables par voie orale pour le traitement de maladies allergiques, telles que l'asthme, la rhinite allergique et la dermatite atopique.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0800874A GB0800874D0 (en) | 2008-01-18 | 2008-01-18 | Compounds having CRTH2 antagonist activity |
| GB0820526A GB0820526D0 (en) | 2008-11-10 | 2008-11-10 | Compounds having crth2 antagonist activity |
| PCT/GB2009/000142 WO2009090414A1 (fr) | 2008-01-18 | 2009-01-19 | Composés présentant une activité antagoniste de crth2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA32075B1 true MA32075B1 (fr) | 2011-02-01 |
Family
ID=40473418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA33081A MA32075B1 (fr) | 2008-01-18 | 2010-08-13 | Composes presentant une activite antagoniste de crth2 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20090186923A1 (fr) |
| EP (1) | EP2250161B1 (fr) |
| JP (2) | JP2011509988A (fr) |
| KR (1) | KR101644170B1 (fr) |
| CN (1) | CN101932571B (fr) |
| AU (1) | AU2009204700B2 (fr) |
| BR (1) | BRPI0906786B1 (fr) |
| CA (1) | CA2712017C (fr) |
| CY (1) | CY1114748T1 (fr) |
| DK (1) | DK2250161T3 (fr) |
| ES (1) | ES2442717T3 (fr) |
| HR (1) | HRP20140045T1 (fr) |
| IL (1) | IL206959A (fr) |
| MA (1) | MA32075B1 (fr) |
| MX (1) | MX2010007833A (fr) |
| MY (1) | MY155133A (fr) |
| NZ (1) | NZ587251A (fr) |
| PL (1) | PL2250161T3 (fr) |
| PT (1) | PT2250161E (fr) |
| RS (1) | RS53142B (fr) |
| RU (1) | RU2503672C2 (fr) |
| SI (1) | SI2250161T1 (fr) |
| WO (1) | WO2009090414A1 (fr) |
| ZA (1) | ZA201005799B (fr) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6962940B2 (en) | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
| GB0324763D0 (en) * | 2003-10-23 | 2003-11-26 | Oxagen Ltd | Use of compounds in therapy |
| WO2009061681A2 (fr) * | 2007-11-06 | 2009-05-14 | Amira Pharmaceuticals, Inc | Antagonistes de récepteurs pgd2 |
| US20100280049A1 (en) * | 2007-11-06 | 2010-11-04 | Amira Pharmaceuticals, Inc. | Antagonists of pgd2 receptors |
| US20110124683A1 (en) * | 2007-11-13 | 2011-05-26 | Oxagen Limited | Use of CRTH2 Antagonist Compounds |
| DK2250161T3 (da) * | 2008-01-18 | 2014-01-27 | Atopix Therapeutics Ltd | Forbindelser med CRTH2-antagonistaktivitet |
| US7750027B2 (en) * | 2008-01-18 | 2010-07-06 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
| EP2240444A1 (fr) * | 2008-01-22 | 2010-10-20 | Oxagen Limited | Composés présentant une activité antagoniste de crth2 |
| WO2009093026A1 (fr) * | 2008-01-22 | 2009-07-30 | Oxagen Limited | Composés présentant une activité antagoniste du récepteur crth2 |
| US8067445B2 (en) | 2008-02-01 | 2011-11-29 | Panmira Pharmaceuticals, Llc | N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors |
| EP2257536A4 (fr) * | 2008-02-14 | 2011-03-23 | Amira Pharmaceuticals Inc | Composés diaryliques cycliques en tant qu'antagonistes de récepteurs de prostaglandine d2 |
| US8497381B2 (en) | 2008-02-25 | 2013-07-30 | Panmira Pharmaceuticals, Llc | Antagonists of prostaglandin D2 receptors |
| US8426449B2 (en) * | 2008-04-02 | 2013-04-23 | Panmira Pharmaceuticals, Llc | Aminoalkylphenyl antagonists of prostaglandin D2 receptors |
| US20110112134A1 (en) * | 2008-05-16 | 2011-05-12 | Amira Pharmaceuticals, Inc. | Tricyclic Antagonists of Prostaglandin D2 Receptors |
| EP2300425A4 (fr) * | 2008-06-24 | 2012-03-21 | Panmira Pharmaceuticals Llc | Antagonistes de cycloalcaneýb¨indole de récepteurs de prostaglandine d2 |
| MX2010014172A (es) | 2008-07-03 | 2011-02-22 | Amira Pharmaceuticals Inc | Antagonistas de receptores de prostaglandina d2. |
| GB2463788B (en) * | 2008-09-29 | 2010-12-15 | Amira Pharmaceuticals Inc | Heteroaryl antagonists of prostaglandin D2 receptors |
| WO2010039977A2 (fr) | 2008-10-01 | 2010-04-08 | Amira Pharmaceuticals, Inc. | Antagonistes d’hétéroaryle des récepteurs de la prostaglandine d2 |
| US8524748B2 (en) | 2008-10-08 | 2013-09-03 | Panmira Pharmaceuticals, Llc | Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors |
| GB2465062B (en) * | 2008-11-06 | 2011-04-13 | Amira Pharmaceuticals Inc | Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors |
| US8383654B2 (en) | 2008-11-17 | 2013-02-26 | Panmira Pharmaceuticals, Llc | Heterocyclic antagonists of prostaglandin D2 receptors |
| WO2011014587A2 (fr) * | 2009-07-31 | 2011-02-03 | Amira Pharmaceuticals, Inc. | Compositions pharmaceutiques ophtalmiques d'antagonsites du récepteur dp2 |
| KR20120047273A (ko) * | 2009-08-05 | 2012-05-11 | 판미라 파마슈티칼스, 엘엘씨 | Dp2 길항제 및 이의 용도 |
| US10391059B2 (en) | 2009-11-11 | 2019-08-27 | Rapamycin Holdings, Inc. | Oral rapamycin nanoparticle preparations and use |
| MX2012007927A (es) | 2010-01-06 | 2012-08-15 | Panmira Pharmaceuticals Llc | Antagonistas de dp2 y usos del mismo. |
| MX2012010820A (es) | 2010-03-22 | 2012-10-10 | Actelion Pharmaceuticals Ltd | Derivados de 3-(heteroaril-amino)-1, 2, 3, 4-tetrahidro-9h-carbazo l y sus uso como moduladores del receptor de prostaglandina d2. |
| GB201103837D0 (en) | 2011-03-07 | 2011-04-20 | Oxagen Ltd | Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid |
| WO2012140612A1 (fr) | 2011-04-14 | 2012-10-18 | Actelion Pharmaceuticals Ltd | Dérivés d'acide 7-(hétéroaryl-amino)-6,7,8,9-tétrahydropyrido[1,2-a]indolacétique et leur utilisation en tant que modulateurs du récepteur aux prostaglandines d2 |
| US9233098B2 (en) | 2011-11-17 | 2016-01-12 | Kbp Biosciences Co., Ltd. | Nitrogen-containing fused ring compounds as CRTH2 antagonists |
| GB201121557D0 (en) | 2011-12-15 | 2012-01-25 | Oxagen Ltd | Process |
| CN104114169A (zh) * | 2011-12-16 | 2014-10-22 | 阿托佩斯治疗有限公司 | 用于治疗嗜酸细胞性食管炎的crth2拮抗剂和质子泵抑制剂的组合物 |
| BR112015000392A2 (pt) * | 2012-07-10 | 2017-06-27 | Hoffmann La Roche | novos indazóis para o tratamento e profilaxia da infecção por vírus sincicial respiratório |
| UY35165A (es) | 2012-12-04 | 2014-06-30 | Takeda Pharmaceutical | Método profiláctico o terapéutico para el síndrome de sjogren |
| US9872854B2 (en) * | 2013-03-14 | 2018-01-23 | Celgene Corporation | Methods for the treatment of psoriatic arthritis using apremilast |
| GB201322273D0 (en) * | 2013-12-17 | 2014-01-29 | Atopix Therapeutics Ltd | Process |
| PH12016501764B1 (en) | 2014-03-17 | 2024-05-17 | Idorsia Pharmaceuticals Ltd | Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators |
| WO2015140701A1 (fr) | 2014-03-18 | 2015-09-24 | Actelion Pharmaceuticals Ltd | Dérivés d'acide aza-indol-acétique et leur utilisation comme modulateurs des récepteurs de la prostaglandine d2 |
| GB201407820D0 (en) * | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
| GB201407813D0 (en) * | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
| GB201407807D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
| JPWO2015190316A1 (ja) * | 2014-06-09 | 2017-04-20 | 住友化学株式会社 | ピリジン化合物の製造方法 |
| WO2016025686A1 (fr) | 2014-08-15 | 2016-02-18 | Celgene Corporation | Dosage d'aprémilast pour le traitement de maladies améliorées par l'inhibition de pde4 |
| WO2017046125A1 (fr) | 2015-09-15 | 2017-03-23 | Actelion Pharmaceuticals Ltd | Formes cristallines |
| KR20200037857A (ko) | 2017-08-14 | 2020-04-09 | 알러간, 인코포레이티드 | 3,4-이치환된 3-시클로부텐-1,2-디온 및 그의 용도 |
| WO2020143793A1 (fr) * | 2019-01-10 | 2020-07-16 | 石药集团中奇制药技术(石家庄)有限公司 | Sels de composé hétérocyclique et utilisation associée |
| CN114796264A (zh) * | 2021-01-27 | 2022-07-29 | 北京北工大科技园有限公司 | 金络合物在制备治疗新型冠状病毒肺炎的药物中的应用 |
| EP4165009A4 (fr) * | 2020-06-12 | 2024-10-02 | Nucmito Pharmaceuticals Co., Ltd. | Composés d'indène, compositions pharmaceutiques de ceux-ci et leurs applications thérapeutiques |
| US12102622B2 (en) | 2021-02-10 | 2024-10-01 | Iolyx Therapeutics, Inc. | Methods for ophthalmic delivery of roflumilast |
| EP4337628A4 (fr) * | 2021-05-15 | 2025-08-27 | Nucmito Pharmaceuticals Company Ltd | Composés indènes, compositions pharmaceutiques à base de ceux-ci et leurs applications thérapeutiques |
| US12263160B2 (en) | 2021-09-22 | 2025-04-01 | Iolyx Therapeutics, Inc. | Methods of treating ocular inflammatory diseases |
| CN115192584A (zh) * | 2022-06-09 | 2022-10-18 | 南方科技大学 | 一种纳米药物及其制备方法和应用 |
| EP4619369A1 (fr) * | 2022-11-16 | 2025-09-24 | Nucmito Pharmaceuticals Co., Ltd. | Composés indène, compositions pharmaceutiques de ceux-ci et leurs applications thérapeutiques |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3557142A (en) | 1968-02-20 | 1971-01-19 | Sterling Drug Inc | 4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters |
| BE790679A (fr) | 1971-11-03 | 1973-04-27 | Ici Ltd | Derives de l'indole |
| GB1407658A (en) | 1973-03-06 | 1975-09-24 | Ici Ltd | Process for the manufacture of indole derivatives |
| GB1460348A (en) | 1974-02-04 | 1977-01-06 | Ici Ltd | Quinazoline derivativesa |
| DK151884C (da) | 1979-03-07 | 1988-06-13 | Pfizer | Analogifremgangsmaade til fremstilling af 3-(1-imidazolylalkyl)indolderivater eller farmaceutisk acceptable syreadditionssalte deraf |
| US4363912A (en) | 1980-12-15 | 1982-12-14 | Pfizer Inc. | Indole thromboxane synthetase inhibitors |
| GB8607294D0 (en) | 1985-04-17 | 1986-04-30 | Ici America Inc | Heterocyclic amide derivatives |
| GB9122590D0 (en) | 1991-10-24 | 1991-12-04 | Lilly Industries Ltd | Pharmaceutical compounds |
| DE69734141T2 (de) | 1996-06-05 | 2006-07-13 | Bml Inc. | PROTEIN, DAS FÜR MENSCHLICHE Th2-ZELLEN SPEZIFISCH IST, DAFÜR KODIERENDES GEN UND KORRESPONDIERENDE TRANSFORMANTE, REKOMBINANTER VEKTOR UND MONOKLONALER ANTKÖRPER |
| US6916841B2 (en) | 1998-02-25 | 2005-07-12 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
| AP2000001929A0 (en) | 1998-03-31 | 2000-09-30 | Inst For Pharm Discovery Inc | Substituted indolealkanoic acids. |
| TNSN99224A1 (fr) | 1998-12-01 | 2005-11-10 | Inst For Pharm Discovery Inc | Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique |
| GB9902461D0 (en) * | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| ATE315230T1 (de) | 1999-08-23 | 2006-02-15 | Bml Inc | Verfahren zum identifizieren von prostaglandin d2 rezeptor modulatoren |
| WO2001051849A1 (fr) | 2000-01-14 | 2001-07-19 | Koninklijke Philips Electronics N.V. | Dispositif d'affichage |
| US6521659B2 (en) | 2000-03-02 | 2003-02-18 | Institute For Pharmaceutical Discovery, Llc | Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor |
| JP2001247570A (ja) | 2000-03-08 | 2001-09-11 | Japan Tobacco Inc | インドール酢酸化合物及びその製造方法 |
| US6878522B2 (en) | 2000-07-07 | 2005-04-12 | Baiyong Li | Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2 |
| SE0200356D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| SE0200411D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| EP2423190A1 (fr) | 2002-05-16 | 2012-02-29 | Shionogi&Co., Ltd. | Composés présentant un antagonisme du récepteur PGD 2 |
| WO2003097042A1 (fr) | 2002-05-16 | 2003-11-27 | Shionogi & Co., Ltd. | Antagoniste de recepteur de pdg2 |
| SE0201635D0 (sv) | 2002-05-30 | 2002-05-30 | Astrazeneca Ab | Novel compounds |
| TW200307542A (en) | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
| SE0202241D0 (sv) * | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
| US7364647B2 (en) | 2002-07-17 | 2008-04-29 | Eksigent Technologies Llc | Laminated flow device |
| ES2401079T3 (es) | 2002-12-20 | 2013-04-16 | Amgen Inc. | Moduladores del asma y de la inflamación alérgica |
| JP4324418B2 (ja) | 2003-08-05 | 2009-09-02 | 株式会社日立国際電気 | 基板処理装置および半導体デバイスの製造方法 |
| SE0302232D0 (sv) | 2003-08-18 | 2003-08-18 | Astrazeneca Ab | Novel Compounds |
| JP2007508363A (ja) * | 2003-10-14 | 2007-04-05 | オキサジェン リミテッド | Crth2アンタゴニスト活性を有する化合物 |
| GB0324763D0 (en) * | 2003-10-23 | 2003-11-26 | Oxagen Ltd | Use of compounds in therapy |
| RU2376286C2 (ru) | 2004-03-11 | 2009-12-20 | Актелион Фармасьютиклз Лтд | Производные индол-1-илуксусной кислоты |
| WO2005102338A1 (fr) * | 2004-04-20 | 2005-11-03 | Pfizer Limited | Methode de traitement de la douleur neuropathique au moyen d'un antagoniste du recepteur crth2 |
| BRPI0515532A (pt) | 2004-09-21 | 2008-07-29 | Athersys Inc | composto, composição farmacêutica, métodos de inibir a ligação de ligandos endógenos ao receptor de crth-2 em uma célula, de tratar, melhorar ou prevenir um distúrbio responsivo à inibição da ligação de ligandos endógenos ao receptor de crt-2 e de preparar um composto, e, kit |
| GB0504150D0 (en) | 2005-03-01 | 2005-04-06 | Oxagen Ltd | Microcrystalline material |
| GB0505048D0 (en) | 2005-03-11 | 2005-04-20 | Oxagen Ltd | Compounds with PGD antagonist activity |
| PL65781Y1 (pl) | 2005-08-16 | 2012-02-29 | Katarzyna Kawczyńska | Wkładka kosmetyczna |
| ES2391671T3 (es) | 2006-07-22 | 2012-11-28 | Oxagen Limited | Compuestos con actividad antagonista de CRTH2 |
| GB0722203D0 (en) * | 2007-11-13 | 2007-12-19 | Oxagen Ltd | Use of CRTH2 antagonist compounds |
| JP5327762B2 (ja) * | 2007-12-14 | 2013-10-30 | プルマジェン セラピューティクス(アズマ)リミテッド | インドールおよびその治療的使用 |
| DK2250161T3 (da) * | 2008-01-18 | 2014-01-27 | Atopix Therapeutics Ltd | Forbindelser med CRTH2-antagonistaktivitet |
-
2009
- 2009-01-19 DK DK09702598.5T patent/DK2250161T3/da active
- 2009-01-19 WO PCT/GB2009/000142 patent/WO2009090414A1/fr not_active Ceased
- 2009-01-19 BR BRPI0906786-8A patent/BRPI0906786B1/pt not_active IP Right Cessation
- 2009-01-19 RS RS20140016A patent/RS53142B/sr unknown
- 2009-01-19 CN CN200980103456.8A patent/CN101932571B/zh not_active Expired - Fee Related
- 2009-01-19 RU RU2010129027/04A patent/RU2503672C2/ru active
- 2009-01-19 KR KR1020107017661A patent/KR101644170B1/ko not_active Expired - Fee Related
- 2009-01-19 JP JP2010542688A patent/JP2011509988A/ja active Pending
- 2009-01-19 MX MX2010007833A patent/MX2010007833A/es active IP Right Grant
- 2009-01-19 HR HRP20140045AT patent/HRP20140045T1/hr unknown
- 2009-01-19 EP EP09702598.5A patent/EP2250161B1/fr active Active
- 2009-01-19 ES ES09702598.5T patent/ES2442717T3/es active Active
- 2009-01-19 PL PL09702598T patent/PL2250161T3/pl unknown
- 2009-01-19 MY MYPI2010003390A patent/MY155133A/en unknown
- 2009-01-19 SI SI200930822T patent/SI2250161T1/sl unknown
- 2009-01-19 PT PT97025985T patent/PT2250161E/pt unknown
- 2009-01-19 AU AU2009204700A patent/AU2009204700B2/en not_active Ceased
- 2009-01-19 NZ NZ587251A patent/NZ587251A/en not_active IP Right Cessation
- 2009-01-19 CA CA2712017A patent/CA2712017C/fr active Active
- 2009-01-21 US US12/356,822 patent/US20090186923A1/en not_active Abandoned
-
2010
- 2010-07-12 IL IL206959A patent/IL206959A/en active IP Right Grant
- 2010-08-13 MA MA33081A patent/MA32075B1/fr unknown
- 2010-08-13 ZA ZA2010/05799A patent/ZA201005799B/en unknown
-
2014
- 2014-01-15 CY CY20141100031T patent/CY1114748T1/el unknown
- 2014-05-07 JP JP2014095946A patent/JP5855162B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2010007833A (es) | Compuestos que tienen actividad antagonista de crth2. | |
| ES2528797T3 (es) | Compuestos de aza-benzotiofenilo y métodos de uso | |
| PE20211203A1 (es) | Compuestos para el tratamiento de trastornos dependientes de cinasas | |
| ES2588102T3 (es) | Derivados de 5-fluoro-pirimidina disustituidos que contienen un grupo sulfoximina | |
| EA201101089A1 (ru) | Производные оксадиазола в качестве агонистов рецептора s1p1 | |
| AR084976A1 (es) | Compuestos de bifenileno sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales | |
| CY1114141T1 (el) | Ενωσεις που εχουν ανταγωνιστικη του crth2 δραστηριοτητα | |
| MA37142A3 (fr) | Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine | |
| EA200601620A1 (ru) | 5,6-диалкил-7-аминотриазолопиримидины, способ их получения и их применение для борьбы с патогенными растениями, а также содержащие их средства | |
| EA201170096A1 (ru) | Замещенные производные пиримидона | |
| MA33721B1 (fr) | Derives sulfonamides heterocycliques utilises comme inhibiteurs de mek | |
| EA200970793A1 (ru) | Модуляторы рецепторов, активируемых пролифераторами пероксисом | |
| NO20072409L (no) | Substituerte n-sulfonylaminobenzyl-2-fenoksy acetamid-forbindelser | |
| MY169179A (en) | Novel piperidine compound or salt thereof | |
| EA201000104A1 (ru) | Производные пиримидина, применимые для лечения воспалительных или аллергических патологических состояний | |
| EA201391537A1 (ru) | ЭТИНИЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ mGluR5 | |
| MX2024003472A (es) | Derivados del lsd, sintesis y metodo para el tratamiento de enfermedades y trastornos. | |
| MA67105B1 (fr) | Agonistes inverses de pparg et leurs utilisations | |
| MX385971B (es) | Compuesto de griseofulvina. | |
| WO2009118473A3 (fr) | Composés dérivés d'azétidines, leur préparation et leur application en thérapeutique | |
| PL408251A1 (pl) | Skondensowane pochodne triazolu jako inhibitory fosfodiesterazy 10A | |
| HRP20041087B1 (hr) | Derivati n-acilaminobenzena kao selektivni inhibitori monoamin oksidaze b | |
| RU2012146325A (ru) | Терапевтическое средство или профилактическое средство для лечения фибромиалгии | |
| MA29343B1 (fr) | Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine | |
| TW200716527A (en) | Substituted aminoalkyl-and amidoalkyl-benzopyran derivatives |